- 23rd OctOctober
- 24th OctOctober
- 6th NovNovember
- 7th NovNovember
- 13th NovNovember
All times listed below are Eastern Time. Please adjust accordingly for your timezone.
23 23rd
-
Opening Remarks
Robert J. Mayer MD – Course Director
Women’s Cancers
Track Leader: Dr. Burstein
-
Molecular Advances and Emerging Treatment Strategies in Ovarian and Endometrial Cancers
Ursula A. Matulonis MD -
HER2-Positive and Triple-Negative Breast Cancers: An Evolving Treatment Landscape
Eric P. Winer MD -
Advances in Hormone Receptor Positive Breast Cancer and Hereditary Breast Cancer Syndromes
Harold J. Burstein MD, PhD -
Session Break
Supportive Care
Moderator: Dr. Burstein
-
Supportive and Palliative Care: Managing Symptoms and Toxicities to Improve Patient Outcomes
Janet L. Abrahm MD -
Optimizing Outcomes for Survivors of Cancer
Ann H. Partridge MD, MPH -
Panel Discussion
All Faculty
-
Closing Remarks
24 24th
-
Opening Remarks
Robert J. Mayer MD – Course Director
Hematologic Malignancies
Moderator: Dr. Connors
-
Non-Hodgkin and Hodgkin Lymphoma: An Individualized Treatment Approach
Ann S. LaCasce MD, MMSC -
Myeloid Malignancies: Molecular Markers and Targeted Therapies
Richard M. Stone MD -
Molecular Drivers of Myeloproliferative Neoplasms: Impact on Diagnosis, Assessment, and Management
Ayalew Tefferi MD -
Multiple Myeloma: Current Evidence-Based Management
Kenneth C. Anderson MD -
Session Break
-
Chronic Lymphocytic Leukemia: Evaluating the Rapidly Changing Treatment Landscape
John C. Byrd MD -
Cancer Associated Venous Thromboembolic Disease: Current Guidance and Clinical Data
Jean M. Connors MD -
Panel Discussion
All Faculty
-
Closing Remarks
6 6th
-
Opening Remarks
Robert J. Mayer MD – Course Director
Sarcoma
Moderator: Dr. Mayer
-
Best Practices and Expanding Treatment Options in Soft Tissue Sarcoma
George D. Demetri MD
Gastrointestinal Cancers
Moderator: Dr. Mayer
-
Novel Approaches for the Management of Esophageal, Gastric, and Pancreatic Cancers
Peter C. Enzinger MD -
Hereditary Gastrointestinal Cancers: From Family History to Management with Combination Therapy
Matthew B. Yurgelun MD -
Session Break
-
Reducing Risk: Current Clinical Evidence on Lifestyle Management and Chemopreventative Agents in Gastrointestinal Cancer
Charles S. Fuchs MD, MPH -
Colorectal Cancer: Molecular Markers and Evidence-Based Best Practices for Systemic Treatment
Robert J. Mayer MD -
Panel Discussion
All Faculty
-
Closing Remarks
7 7th
-
Opening Remarks
Robert J. Mayer MD – Course Director
Head, Neck and Lung Cancers
Moderator: Dr. Johnson
-
Emerging Agents in the Multimodal Management of Head, Neck, and Thyroid Cancers
Robert I. Haddad MD -
NSCLC and SCLC: Molecular Testing and Emerging Treatment Options
Bruce E. Johnson MD -
Session Break
Melanoma Cancer
Track Leader: Dr. Johnson
-
Evidence-Based Treatment Approaches for Adjuvant, Advanced, and Metastatic Melanoma
F. Stephen Hodi MD -
Panel Discussion
All Faculty
-
Closing Remarks
13 13th
-
Opening Remarks
Robert J. Mayer MD – Course Director
Moderator: Dr. Johnson
-
COVID and Cancer Treatment
Amy C. Bessnow MD, MPH
Genitourinary Cancers
Moderator: Dr. Johnson
-
Prostate Cancer: An Evolving Treatment Landscape
William K. Oh MD -
Session Break
-
Treatment Selection in Renal Cell and Urothelial Carcinoma: Integrating Novel Agents into Daily Practice
Robert Dreicer MD -
Panel Discussion
All Faculty
-
Closing Remarks